Anwar A. Hoosen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Anwar A. Hoosen has a total of 47 co-authors. Here are the top co-authors by number of shared publications:
- Adele Visser
Department of Philosophy, Practical and Systematic Theology, School of Humanities, University of South Africa, Pretoria
2 shared publications - Kamaldeen Baba
Universitas Academic Laboratory, University of the Free State, Bloemfontein 9300, South Africa
2 shared publications - Alison Heald
Targeted Genetics Corp.; Seattle, WA USA
1 shared publication - Andrew Ken Lacey Robinson
Department of Health, North West Province, South Africa.
1 shared publication - Andrew McMichael
Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, England OX3 9DS, UK
1 shared publication - Andries W Dreyer
Department of Medical Microbiology, University of Pretoria, Pretoria, South Africa
1 shared publication
Latest Publications
- Open Access
- 3 May 2012
- Published by Springer Nature in BMC Research Notes
- Vol. 5 (1) , 215
In vitro activity of tigecycline against clinical isolates of carbapenem resistant Acinetobacter baumannii complex in Pretoria, South Africa
The presence of multi-drug resistant Acinetobacter baumannii raises a big therapeutic challenge in our hospital. Tigecycline, a new glycylcycline with expanded broad spectrum of activity against multi-drug resistant organisms was recently licensed in South Africa.
- 3 May 2012
- Published by Springer Nature in BMC Research Notes
- Vol. 5 (1) , 215
Open AccessIn vitro activity of tigecycline against clinical isolates of carbapenem resistant Acinetobacter baumannii complex in Pretoria, South Africa
The presence of multi-drug resistant Acinetobacter baumannii raises a big therapeutic challenge in our hospital. Tigecycline, a new glycylcycline with expanded broad spectrum of activity against multi-drug resistant organisms was recently licensed in South Africa.
- 1 May 2012
- Published by Taylor & Francis in Human Vaccines & Immunotherapeutics
- Vol. 8 (5) , 630-638
Background morbidity in HIV vaccine trial participants from various geographic regions as assessed by unsolicited adverse events
Background Recently, more clinical trials are being conducted in Africa and Asia, therefore, background morbidity in the respective populations is of interest. Between 2000 and 2007, the International AIDS Vaccine Initiative sponsored 19 Phase 1 or 2A preventive HIV vaccine trials in the US, Europe, Sub-Saharan Africa and India, enrolling 900 healthy HIV-1 uninfected volunteers. Objective To assess background morbidity as reflected by unsolicited adverse events (AEs), unrelated to study vaccine, reported in clinical trials from four continents. Methods All but three clinical trials were double-blind, randomized and placebo-controlled. Study procedures and data collection methods were standardized. The frequency and severity of AEs reported during the first year of the trials were analyzed. To avoid confounding by vaccine-related events, solicited reactogenicity and other AEs occurring within 28 d after any vaccination were excluded. Results In total, 2134 AEs were reported by 76% of all participants; 73% of all events were mild. The rate of AEs did not differ between placebo and vaccine recipients. Overall, the percentage of participants with any AE was higher in Africa (83%) compared with Europe (71%), US (74%) and India (65%), while the percentage of participants with AEs of moderate or greater severity was similar in all regions except India. In all regions, the most frequently reported AEs were infectious diseases, followed by gastrointestinal disorders. Conclusions Despite some regional differences, in these healthy participants selected for low risk of HIV infection, background morbidity posed no obstacle to clinical trial conduct and interpretation. Data from controlled clinical trials of preventive interventions can offer valuable insights into the health of the eligible population.
- 1 May 2012
- Published by Taylor & Francis in Human Vaccines & Immunotherapeutics
- Vol. 8 (5) , 630-638
Background morbidity in HIV vaccine trial participants from various geographic regions as assessed by unsolicited adverse events
Background Recently, more clinical trials are being conducted in Africa and Asia, therefore, background morbidity in the respective populations is of interest. Between 2000 and 2007, the International AIDS Vaccine Initiative sponsored 19 Phase 1 or 2A preventive HIV vaccine trials in the US, Europe, Sub-Saharan Africa and India, enrolling 900 healthy HIV-1 uninfected volunteers. Objective To assess background morbidity as reflected by unsolicited adverse events (AEs), unrelated to study vaccine, reported in clinical trials from four continents. Methods All but three clinical trials were double-blind, randomized and placebo-controlled. Study procedures and data collection methods were standardized. The frequency and severity of AEs reported during the first year of the trials were analyzed. To avoid confounding by vaccine-related events, solicited reactogenicity and other AEs occurring within 28 d after any vaccination were excluded. Results In total, 2134 AEs were reported by 76% of all participants; 73% of all events were mild. The rate of AEs did not differ between placebo and vaccine recipients. Overall, the percentage of participants with any AE was higher in Africa (83%) compared with Europe (71%), US (74%) and India (65%), while the percentage of participants with AEs of moderate or greater severity was similar in all regions except India. In all regions, the most frequently reported AEs were infectious diseases, followed by gastrointestinal disorders. Conclusions Despite some regional differences, in these healthy participants selected for low risk of HIV infection, background morbidity posed no obstacle to clinical trial conduct and interpretation. Data from controlled clinical trials of preventive interventions can offer valuable insights into the health of the eligible population.
- Open Access
- 1 January 2011
- Published by Springer Nature in Annals of Clinical Microbiology and Antimicrobials
- Vol. 10 (1) , 4
Comparison of the VersaTREK blood culture system against the Bactec9240 system in patients with suspected bloodstream infections
To evaluate the VersaTREK (TREK Diagnostic Systems, Cleveland, Ohio) blood culture system against the Bactec9240 (BD Microbiology, Cockeysville, MD), for the recovery of bloodstream pathogens.
- 1 January 2011
- Published by Springer Nature in Annals of Clinical Microbiology and Antimicrobials
- Vol. 10 (1) , 4
Open AccessComparison of the VersaTREK blood culture system against the Bactec9240 system in patients with suspected bloodstream infections
To evaluate the VersaTREK (TREK Diagnostic Systems, Cleveland, Ohio) blood culture system against the Bactec9240 (BD Microbiology, Cockeysville, MD), for the recovery of bloodstream pathogens.
- Open Access
- 1 January 2010
- Published by Taylor & Francis in Southern African Journal of Epidemiology and Infection
- Vol. 25 (4) , 7-10
Mycoplasma genitalium: a brief review
Mycoplasma genitalium belongs to the class Mollicutes and is the smallest prokaryote capable of independent replication. It was originally isolated from the urethras of two men with non-gonococcal urethritis (NGU). It has a number of characteristics which are similar to its genetically close relative, Mycoplasma pneumoniae, which is an established pathogen of the respiratory tract. M. genitalium lacks a cell wall and has a characteristic pear/fask shape with a terminal tip organelle. This organelle enables M. genitalium to glide along and adhere to moist/mucous surfaces, including host cells. M. genitalium has minimal metabolism, and when compared to the other genital mycoplasmas, has the ability to metabolise glucose. The organism is the smallest self-replicating prokaryote with a genome of only 580 kb pairs and was the second bacterium to have its genome fully sequenced. Its DNA falls under the low G+C category and thus has a lower melting temperature during denaturation in polymerase chain reaction (PCR) assays. The target genes for PCR assays include MgPa, rRNA and gap. M. genitalium has several virulence factors that are responsible for its pathogenicity. These include the ability to adhere to host epithelial cells using the terminal tip organelle with its adhesins, the release of enzymes and the ability to evade the host immune response by antigenic variation.
- 1 January 2010
- Published by Taylor & Francis in Southern African Journal of Epidemiology and Infection
- Vol. 25 (4) , 7-10
Open AccessMycoplasma genitalium: a brief review
Mycoplasma genitalium belongs to the class Mollicutes and is the smallest prokaryote capable of independent replication. It was originally isolated from the urethras of two men with non-gonococcal urethritis (NGU). It has a number of characteristics which are similar to its genetically close relative, Mycoplasma pneumoniae, which is an established pathogen of the respiratory tract. M. genitalium lacks a cell wall and has a characteristic pear/fask shape with a terminal tip organelle. This organelle enables M. genitalium to glide along and adhere to moist/mucous surfaces, including host cells. M. genitalium has minimal metabolism, and when compared to the other genital mycoplasmas, has the ability to metabolise glucose. The organism is the smallest self-replicating prokaryote with a genome of only 580 kb pairs and was the second bacterium to have its genome fully sequenced. Its DNA falls under the low G+C category and thus has a lower melting temperature during denaturation in polymerase chain reaction (PCR) assays. The target genes for PCR assays include MgPa, rRNA and gap. M. genitalium has several virulence factors that are responsible for its pathogenicity. These include the ability to adhere to host epithelial cells using the terminal tip organelle with its adhesins, the release of enzymes and the ability to evade the host immune response by antigenic variation.
- Open Access
- 14 March 2008
- Published by Springer Nature in BMC Infectious Diseases
- Vol. 8 (1) , 35
Evaluation of immune responses in HIV infected patients with pleural tuberculosis by the QuantiFERON®TB-Gold interferon-gamma assay
Background: Diagnosis of tuberculous (TB) pleuritis is difficult and better diagnostic tools are needed. New blood based interferon-gamma (IFN-γ) tests are promising, but sensitivity could be low in HIV positive patients. The IFN-γ tests have not yet been validated for use in pleural fluid, a compartment with higher level of immune activation than in blood.Methods: The QuantiFERON TB®-Gold (QFT-TB) test was analysed in blood and pleural fluid from 34 patients presenting with clinically suspected pleural TB. Clinical data, HIV status and CD4 cell counts were recorded. Adenosine deaminase activity (ADA) analysis and TB culture were performed on pleural fluid.Results: The patients were categorised as 'confirmed TB' (n = 12), 'probable TB' (n = 16) and 'non-TB' pleuritis (n = 6) based on TB culture results and clinical and biochemical criteria. The majority of the TB patients were HIV infected (82%). The QFT-TB in pleural fluid was positive in 27% and 56% of the 'confirmed TB' and 'probable TB' cases, respectively, whereas the corresponding sensitivities in blood were 58% and 83%. Indeterminate results in blood (25%) were caused by low phytohemagglutinin (PHA = positive control) IFN-γ responses, significantly lower in the TB patients as compared to the 'non-TB' cases (p = 0.02). Blood PHA responses correlated with CD4 cell count (r = 0.600, p = 0.028). In contrast, in pleural fluid indeterminate results (52%) were caused by high Nil (negative control) IFN-γ responses in both TB groups. Still, the Nil IFN-γ responses were lower than the TB antigen responses (p < 0.01), offering a conclusive test for half of the patients. We did not find any correlation between blood CD4 cell count and IFN-γ responses in pleural fluid.Conclusion: The QFT-TB test in blood could contribute to the diagnosis of TB pleuritis in the HIV positive population. Still, the number of inconclusive results is too high to recommend the commercial QFT-TB test for routine use in pleural fluid in a TB/HIV endemic resource-limited setting.
- 14 March 2008
- Published by Springer Nature in BMC Infectious Diseases
- Vol. 8 (1) , 35
Open AccessEvaluation of immune responses in HIV infected patients with pleural tuberculosis by the QuantiFERON®TB-Gold interferon-gamma assay
Background: Diagnosis of tuberculous (TB) pleuritis is difficult and better diagnostic tools are needed. New blood based interferon-gamma (IFN-γ) tests are promising, but sensitivity could be low in HIV positive patients. The IFN-γ tests have not yet been validated for use in pleural fluid, a compartment with higher level of immune activation than in blood.Methods: The QuantiFERON TB®-Gold (QFT-TB) test was analysed in blood and pleural fluid from 34 patients presenting with clinically suspected pleural TB. Clinical data, HIV status and CD4 cell counts were recorded. Adenosine deaminase activity (ADA) analysis and TB culture were performed on pleural fluid.Results: The patients were categorised as 'confirmed TB' (n = 12), 'probable TB' (n = 16) and 'non-TB' pleuritis (n = 6) based on TB culture results and clinical and biochemical criteria. The majority of the TB patients were HIV infected (82%). The QFT-TB in pleural fluid was positive in 27% and 56% of the 'confirmed TB' and 'probable TB' cases, respectively, whereas the corresponding sensitivities in blood were 58% and 83%. Indeterminate results in blood (25%) were caused by low phytohemagglutinin (PHA = positive control) IFN-γ responses, significantly lower in the TB patients as compared to the 'non-TB' cases (p = 0.02). Blood PHA responses correlated with CD4 cell count (r = 0.600, p = 0.028). In contrast, in pleural fluid indeterminate results (52%) were caused by high Nil (negative control) IFN-γ responses in both TB groups. Still, the Nil IFN-γ responses were lower than the TB antigen responses (p < 0.01), offering a conclusive test for half of the patients. We did not find any correlation between blood CD4 cell count and IFN-γ responses in pleural fluid.Conclusion: The QFT-TB test in blood could contribute to the diagnosis of TB pleuritis in the HIV positive population. Still, the number of inconclusive results is too high to recommend the commercial QFT-TB test for routine use in pleural fluid in a TB/HIV endemic resource-limited setting.